These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34195237)

  • 41. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
    Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
    Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
    J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimated Glomerular Filtration Rate Is Associated With an Increased Risk of Death in Heart Failure Patients With Preserved Ejection Fraction.
    Chen Z; Lin Q; Li J; Wang X; Ju J; Xu H; Shi D
    Front Cardiovasc Med; 2021; 8():643358. PubMed ID: 33981733
    [No Abstract]   [Full Text] [Related]  

  • 45. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
    O'Neal WT; Sandesara PB; Samman-Tahhan A; Kelli HM; Hammadah M; Soliman EZ
    Eur J Prev Cardiol; 2017 Jul; 24(11):1212-1219. PubMed ID: 28482692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.
    Segar MW; Patel KV; Ayers C; Basit M; Tang WHW; Willett D; Berry J; Grodin JL; Pandey A
    Eur J Heart Fail; 2020 Jan; 22(1):148-158. PubMed ID: 31637815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The "Obesity Paradox" in Patients With HFpEF With or Without Comorbid Atrial Fibrillation.
    Guo L; Liu X; Yu P; Zhu W
    Front Cardiovasc Med; 2021; 8():743327. PubMed ID: 35087875
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
    Tsujimoto T; Kajio H
    Eur J Prev Cardiol; 2018 Aug; 25(12):1268-1277. PubMed ID: 29808753
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Philips S; Mullens W; Nijst P; Martens P; Fang JC; Drazner MH; Tang WHW; Pandey A
    Eur J Heart Fail; 2019 May; 21(5):634-642. PubMed ID: 30714658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction.
    Dewan P; Rørth R; Raparelli V; Campbell RT; Shen L; Jhund PS; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Køber L; Komajda M; McKelvie RS; O'Meara E; Pfeffer MA; Pitt B; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    Circ Heart Fail; 2019 Dec; 12(12):e006539. PubMed ID: 31813280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT.
    Dong B; He X; Xue R; Chen Y; Zhao J; Zhu W; Liang W; Wu Z; Wu D; Huang H; Zhou Y; Dong Y; Liu C
    ESC Heart Fail; 2020 Dec; 7(6):3801-3809. PubMed ID: 32964677
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
    Tsujimoto T; Kajio H
    J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
    Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.